Glenmark Pharmaceuticals has informed that it enclosed press release titled ‘Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg’.
The above information is a part of company’s filings submitted to BSE.